Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

ALLO Allogene Therapeutics Inc

2,73

-0,13 (-4,55%)

11 Mai 2024 - Fechado

Atrasado em 15 minutos

DWF Labs Doubles Down on Conflux with $28 Million Invested

Hong Kong, China, June 28th, 2023, Chainwire DWF Labs, the global digital asset market maker, and multi-stage Web3 investment firm, ... Read more
https://www.valuewalk.com/dwf-labs-doubles-down-on-conflux-with-28-million-invested/

Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Click aqui para mais gráficos Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024

Click aqui para mais gráficos Allogene Therapeutics.

Notícias Allogene Therapeutics Inc

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Segunda, 6 de Maio de 2024 (7 dias atrás) • GlobeNewswire Inc.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Sexta, 26 de Abril de 2024 (2 semanas atrás) • GlobeNewswire Inc.

Allogene Therapeutics Announces Q2 Investor Conference Participation
Terça, 9 de Abril de 2024 (1 mês atrás) • GlobeNewswire Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Quinta, 14 de Março de 2024 (2 meses atrás) • GlobeNewswire Inc.

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Terça, 12 de Março de 2024 (2 meses atrás) • GlobeNewswire Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Terça, 5 de Março de 2024 (2 meses atrás) • GlobeNewswire Inc.

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Quarta, 28 de Fevereiro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Form 8-K - Current report
Sexta, 16 de Fevereiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Sexta, 16 de Fevereiro de 2024 (3 meses atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 31 de Janeiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 24 de Janeiro de 2024 (4 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Segunda, 22 de Janeiro de 2024 (4 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Allogene Therapeutics Inc

Índice Bovespa

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições